Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression - Full Text View

Purpose

Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression.

Condition	Intervention	Phase
Bipolar Depression	Drug: Lurasidone Drug: Placebo	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Lurasidone

U.S. FDA Resources

Further study details as provided by Sunovion:

Primary Outcome Measures:

Mean change from baseline in MADRS total score after 6 weeks of treatments [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Proportions of subjects with Adverse Events, discontinuations due to Adverse Events and Serious Adverse Events [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Global severity assessed by the CGI-BP-S score (depression) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Functional impairment assessed by the Sheehan Disability Scale (SDS) total score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment:	358
Study Start Date:	November 2010
Study Completion Date:	August 2012
Primary Completion Date:	August 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Lurasidone 20-120 mg flexible dose	Drug: Lurasidone Tablets 20-120 mg, PM dosing,daily for 6 weeks Other Name: Latuda
Placebo Comparator: Placebo	Drug: Placebo Equivalent to Lurasidone dosing

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provide written informed consent and is 18 to 75 years of age inclusive.
Meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.
Has a lifetime history of at least one bipolar manic or mixed manic episode.
Currently being treated with lithium or divalproex or willing to begin treatment with lithium or divalproex.
Not pregnant or nursing and is not planning pregnancy within the projected duration of the study.
Females of reproductive potential agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after
Good physical health on the basis of medical history, physical examination, and laboratory screening.

Exclusion Criteria:

Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
Any chronic organic disease of the CNS (other than Bipolar I Disorder).
Hospitalization for a manic or mixed episode within the past two months.
Used investigational compound within past 6 months.
Clinically significant history of alcohol or substance abuse within the past 3 months or alcohol or substance dependence within the past 12 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01284517

Show 75 Study Locations

Sponsors and Collaborators

Sunovion

Investigators

Study Director:

Medical Director, MD

Sunovion

More Information

No publications provided

Responsible Party:	Sunovion
ClinicalTrials.gov Identifier:	NCT01284517 History of Changes
Other Study ID Numbers:	D1050292, 2010-019778-34
Study First Received:	January 25, 2011
Last Updated:	August 29, 2012
Health Authority:	United States: Food and Drug Administration United States: Institutional Review Board Canada: Health Canada China: Ministry of Health Colombia: National Institutes of Health Czech Republic: State Institute for Drug Control India: Drugs Controller General of India Japan: Pharmaceuticals and Medical Devices Agency Peru: Ministry of Health Slovakia: State Institute for Drug Control Ukraine: Ministry of Health

Keywords provided by Sunovion:

Bipolar I Depression
Lurasidone
Latuda

Additional relevant MeSH terms:

Bipolar Disorder
Depression
Depressive Disorder
Affective Disorders, Psychotic

Mood Disorders
Mental Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on May 21, 2013

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression (PREVAIL3)